OBI Pharma holds EOP2 meeting with US FDA

OBI Pharma, Inc. has met with the Office of Tissues and Advanced Therapies (OTAT) of the US Food and Drug Administration (FDA) for its End-of-Phase 2 (EOP2) meeting for Adagloxad Simolenin (OBI-822). The meeting was held on January 19, 2017 at the FDA campus in Silver Springs, MD.

Based on the discussion with the FDA, OBI Pharma plans to prepare its for submission to the FDA.